Will NVIDIA Stock Bounce Back?
After the wild market moves during February and March, investors…
Sell
28
BDRX Quote, Financials, Valuation and Earnings
Last price:
$1.40
Seasonality move
:
-21.01%
Day range:
$1.63 - $1.80
52-week range:
$1.14 - $74.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.11x
P/B ratio:
0.10x
Volume:
369.7K
Avg. volume:
3.1M
1-year change:
-92.8%
Market cap:
$1.1M
Revenue:
$474.1K
EPS (TTM):
-$74.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
MREO
Mereo BioPharma Group PLC
|
$15.3M | -$0.01 | -100% | -71.23% | $7.44 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$53.6M | -$0.03 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.65 | $17.97 | $1.1M | -- | $0.00 | 0% | 1.11x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.23 | $1.71 | $60.2M | -- | $0.00 | 0% | 0.33x |
|
MREO
Mereo BioPharma Group PLC
|
$1.90 | $7.44 | $302.1M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.83 | $104.00 | $5M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$57.81 | $81.00 | $4.9B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 1.825 | -- | 1.20x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 4.133 | 36.44% | 2.60x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.724 | -- | -- |
|
NCNA
NuCana PLC
|
-- | 0.371 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | 0.836 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$14.7M | -- | -- | -- | -$9.4M |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Biodexa Pharmaceuticals PLC vs. Competitors
-
Which has Higher Returns BDRX or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -2303.38%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About BDRX or ADAP?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 996.46%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 629.48%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 ADAPAdaptimmune Therapeutics PLC2 3 0 -
Is BDRX or ADAP More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.705, which suggesting that the stock is 70.482% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.845, suggesting its more volatile than the S&P 500 by 184.488%.
-
Which is a Better Dividend Stock BDRX or ADAP?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or ADAP?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.11x versus 0.33x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC1.11x -- -- -- ADAPAdaptimmune Therapeutics PLC0.33x -- $3.2M -$74.2M
-
Which has Higher Returns BDRX or MREO?
Mereo BioPharma Group PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M MREOMereo BioPharma Group PLC-- -$0.05 -- -
What do Analysts Say About BDRX or MREO?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 996.46%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.44 which suggests that it could grow by 291.42%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 MREOMereo BioPharma Group PLC6 0 0 -
Is BDRX or MREO More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.705, which suggesting that the stock is 70.482% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.650, suggesting its less volatile than the S&P 500 by 34.968%.
-
Which is a Better Dividend Stock BDRX or MREO?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or MREO?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Mereo BioPharma Group PLC quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than Mereo BioPharma Group PLC's net income of -$7M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.11x versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC1.11x -- -- -- MREOMereo BioPharma Group PLC-- -- -- -$7M
-
Which has Higher Returns BDRX or NCNA?
NuCana PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About BDRX or NCNA?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 996.46%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 12436.16%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 NCNANuCana PLC0 1 0 -
Is BDRX or NCNA More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.705, which suggesting that the stock is 70.482% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.355%.
-
Which is a Better Dividend Stock BDRX or NCNA?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or NCNA?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than NuCana PLC's net income of -$836.1K. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.11x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC1.11x -- -- -- NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns BDRX or VRNA?
Verona Pharma PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -92.29%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About BDRX or VRNA?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 996.46%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 40.11%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Verona Pharma PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 VRNAVerona Pharma PLC5 0 0 -
Is BDRX or VRNA More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.705, which suggesting that the stock is 70.482% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.165, suggesting its less volatile than the S&P 500 by 83.527%.
-
Which is a Better Dividend Stock BDRX or VRNA?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or VRNA?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Verona Pharma PLC's net income of -$33.8M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.11x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC1.11x -- -- -- VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Energy Transfer a Good Dividend Stock to Buy Now?
Energy Transfer (NYSE:ET) offers an impressive yield, to say the…
Did the Market Bottom Already?
The past few weeks have been among the most volatile…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
78
BMA alert for Apr 15
Banco Macro SA [BMA] is down 2.55% over the past day.
Buy
72
BKTI alert for Apr 15
BK Technologies [BKTI] is up 2.01% over the past day.
Buy
71
GGAL alert for Apr 15
Grupo Financiero Galicia SA [GGAL] is down 3.01% over the past day.
